Mirae Asset Global Investments Co. Ltd. grew its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) by 4.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,858 shares of the company’s stock after purchasing an additional 878 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Pacira BioSciences were worth $805,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Neo Ivy Capital Management acquired a new stake in shares of Pacira BioSciences during the second quarter valued at about $44,000. Quadrant Capital Group LLC boosted its stake in shares of Pacira BioSciences by 380.8% during the third quarter. Quadrant Capital Group LLC now owns 875 shares of the company’s stock valued at $47,000 after purchasing an additional 693 shares in the last quarter. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Pacira BioSciences during the fourth quarter valued at about $39,000. Advisors Asset Management Inc. boosted its stake in shares of Pacira BioSciences by 32.6% during the third quarter. Advisors Asset Management Inc. now owns 1,257 shares of the company’s stock valued at $67,000 after purchasing an additional 309 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Pacira BioSciences during the second quarter valued at about $156,000.
Analyst Ratings Changes
PCRX has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Pacira BioSciences in a research note on Thursday, April 20th. Barclays lowered their price objective on Pacira BioSciences from $90.00 to $80.00 in a research report on Friday, March 3rd. Piper Sandler lowered their price objective on Pacira BioSciences from $63.00 to $62.00 in a research report on Tuesday, April 25th. Royal Bank of Canada lowered their price objective on Pacira BioSciences from $80.00 to $76.00 and set an “outperform” rating for the company in a research report on Wednesday, March 1st. Finally, StockNews.com began coverage on Pacira BioSciences in a research report on Thursday, May 18th. They set a “hold” rating for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences presently has an average rating of “Moderate Buy” and an average target price of $62.73.
Pacira BioSciences Trading Down 3.1 %
Pacira BioSciences (NASDAQ:PCRX – Get Rating) last released its quarterly earnings data on Wednesday, May 3rd. The company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.08). The firm had revenue of $160.34 million for the quarter, compared to the consensus estimate of $157.02 million. Pacira BioSciences had a negative net margin of 1.56% and a positive return on equity of 10.12%. Research analysts forecast that Pacira BioSciences, Inc. will post 2.78 earnings per share for the current year.
Insider Activity
In other news, Director Gary W. Pace sold 5,015 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The stock was sold at an average price of $41.78, for a total transaction of $209,526.70. Following the completion of the sale, the director now owns 139,675 shares in the company, valued at $5,835,621.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.60% of the company’s stock.
Pacira BioSciences Profile
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Articles
- Get a free copy of the StockNews.com research report on Pacira BioSciences (PCRX)
- A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
- Don’t Worry; Sportsman’s Warehouse Will Get Cheaper
- Trinseo’s Dip, Has Something Changed Or Is It Just A Down Cycle
- The Most Upgraded Stocks From The Q1 Earnings Season
- What U-Haul Earnings Are Showing, Heading Up?
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
